2024
Hepatorenal Syndrome Type 1: Diagnosis and Treatment
Belcher J. Hepatorenal Syndrome Type 1: Diagnosis and Treatment. Advances In Kidney Disease And Health 2024, 31: 100-110. PMID: 38649214, DOI: 10.1053/j.akdh.2023.05.001.Peer-Reviewed Original ResearchConceptsAcute kidney injuryHepatorenal syndromeKidney injuryFunctional acute kidney injuryUrinary biomarkers of kidney injuryAssociated with significant morbidityFractional excretion of sodiumNeutrophil gelatinase-associated lipocalinDiagnostic criteriaBiomarkers of kidney injuryMultiple urinary biomarkersOptimal dosing strategiesExcretion of sodiumPoint-of-care ultrasoundAccurate differential diagnosisAnalog of vasopressinSets of diagnostic criteriaAdvanced cirrhosisAlbumin administrationSignificant morbidityVolume resuscitationTherapeutic optionsDosing strategiesFractional excretionDifferential diagnosis
2023
Good Enough? Terlipressin, Hepatorenal Syndrome, and the Usage of RRT
Belcher J. Good Enough? Terlipressin, Hepatorenal Syndrome, and the Usage of RRT. Kidney360 2023, 4: 1011-1013. PMID: 37651662, PMCID: PMC10484352, DOI: 10.34067/kid.0000000000000217.Peer-Reviewed Original ResearchHepatorenal Syndrome Pathophysiology, Diagnosis, and Treatment
Belcher J. Hepatorenal Syndrome Pathophysiology, Diagnosis, and Treatment. Medical Clinics Of North America 2023, 107: 781-792. PMID: 37258014, DOI: 10.1016/j.mcna.2023.03.009.Peer-Reviewed Original ResearchConceptsAcute kidney injuryHepatorenal syndromeCombination of midodrineFirst-line standardPooling of bloodAnalog of vasopressinIntravenous albuminKidney injuryLiver transplantationVasoconstrictor agentsDefinitive treatmentPathophysiologic cascadeSplanchnic systemSyndrome pathophysiologyArterial volumeTreatmentTerlipressinCirrhosisMidodrineOctreotidePatientsTransplantationPathophysiologySyndromeInjuryResponsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
Velez J, Karakala N, Tayebi K, Wickman T, Mohamed M, Kovacic R, Therapondos G, Kanduri S, Allegretti A, Belcher J, Regner K, Wentowski C. Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1. Kidney360 2023, 4: e448-e456. PMID: 36763632, PMCID: PMC10278824, DOI: 10.34067/kid.0000000000000068.Peer-Reviewed Original ResearchConceptsHepatorenal syndrome type 1Mean arterial pressureSyndrome type 1HRS-1Baseline SCrMAP riseType 1Serum creatinineArterial pressureKidney functionDay 14Baseline mean arterial pressureMean mean arterial pressureMedian mean arterial pressureEnd-stage liver diseaseMultivariate logistic regression analysisFavorable renal outcomeOptimal MAP targetsUse of norepinephrineLogistic regression analysisGreater reductionMedian sCrNorepinephrine useVasoconstrictor therapyRenal outcomes
2021
Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward
Belcher JM, Parada XV, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Sharma P, Regner KR, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT, Allegretti AS, Investigators H. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward. American Journal Of Kidney Diseases 2021, 79: 737-745. PMID: 34606933, DOI: 10.1053/j.ajkd.2021.08.016.Peer-Reviewed Original ResearchConceptsAcute kidney injuryHepatorenal syndromeRespiratory adverse eventsPrimary end pointFirst-line therapyMean arterial pressureSympathetic nervous systemSynthetic vasopressin analogueAdvanced cirrhosisHRS reversalAldosterone systemKidney injuryLack of evidenceAdverse eventsMortality benefitPortal pressureArterial pressureFulminant formSplanchnic systemSignificant morbidityRenal vasculatureVasodilatory substancesApparent increased rateTerlipressinCONFIRM trials